Cancer Targeted Technology (CTT) is a biotechnology company commercializing unique small molecule inhibitors to pivotal enzyme targets in cancer.

The company's first product, CTT-54, recognizes the molecular target, Prostate Specific Membrane Antigen, with unique and unexploited binding characteristics. PSMA is an exceptional FDA-approved biomarker for prostate cancer and is expressed on close to 100% of prostate tumors with increase in expression correlated with disease progression and low expression in normal tissue. PSMA is also expressed on the new blood vessels of a variety of non-prostatic solid malignancies, making the utility and broader market for CTT-54, significant.